• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • Q&A
    • Videos
    • Comment
    • Analysis
    • People moves
    • In Profile
  •  
    Analysis
    • Videos
    • Q&A
    • Comment
    • In Profile
    • Podcast
    • Fundraising
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • UK / Ireland

Sofinnova et al. invest £1.3m in Synthace

  • Ellie Pullen
  • 25 September 2013
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Sofinnova Partners has led a ТЃ1.3m funding round for Synthace, a London-based applied synthetic bioengineering company, alongside a syndicate of angel investors.

The fresh capital will be used by Synthace to pursue production of its first chemical products at scale. The company also plans on using the funds to form partnerships with chemical industry players, to eventually take its products to market.

Sofinnova backed the company via its Green Seed Fund, which held its first close in December last year on €22.5m. The Green Seed Fund is focused exclusively on making seed investments to European companies operating in the renewable chemistry and industrial biotechnology industries. CDC Enterprises and industry players Solvay, Sofiprotéol and Unigrains are LPs of the fund, which is managed by Sofinnova partner Joško Bobanović.

In conjunction with the equity injection from Sofinnova and the angel syndicate, Synthace has also secured a £500,000 Technology Strategy Board award from University College London (UCL) and the University of Manchester.

The transaction is believed to mark the second investment from Sofinnova's Green Seed Fund. The first took place in February this year, when the firm jointly injected €2.2m into Finnish start-up MetGen with Finnvera and Finnish Industry Investment.

Company
Synthace is headquartered in London and was founded in 2012 as a spinout from UCL. The company engineers biological systems for the production of speciality chemicals. It does so by harnessing the abilities of micro-organisms from feedstocks to produce chemical products.

Synthace's technology platform, which allows the company to rapidly engineer its products, uses big data analysis with wet lab experimental design and molecular biology tools. Wet labs are laboratories where chemicals or biological materials are handled in liquid solutions.

People
Tim Fell is the CEO of Synthace, while CTO Sean Ward is the company's founder. Sofinnova partner Joško Bobanović is the manager of the firm's Green Seed Fund and has taken up a seat on Synthace's board of directors.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • UK / Ireland
  • Early-stage
  • Healthcare
  • United Kingdom
  • Sofinnova Partners

More on UK / Ireland

Inflexion to exit Xtrac in SBO to MiddleGround Capital
Inflexion to exit Xtrac in SBO to MiddleGround Capital

Sale of UK-based transmission-systems manufacturer marks Buyout Fund IVт€™s seventh exit

  • UK / Ireland
  • 31 July 2023
Federated Hermes raises USD 486m for fifth co-investment fund
Federated Hermes raises USD 486m for fifth co-investment fund

Fund surpassed its USD 400m target; its 2018-vintage predecessor raised USD 600m against a USD 350m target

  • UK / Ireland
  • 12 July 2023
FPE Capital acquires, merges NoBlue and Elevate2
FPE Capital acquires, merges NoBlue and Elevate2

GPт€™s investment in NetSuite partners marks fifth investment out of third fund

  • UK / Ireland
  • 11 July 2023
Palatine reaps 6x money on SBO of Anthesis to Carlyle
Palatine reaps 6x money on SBO of Anthesis to Carlyle

GP will be reinvesting in UK-headquartered sustainability firm, acquiring a minority stake

  • UK / Ireland
  • 03 July 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013